SG11202004005RA - Pharmaceutical compositions for controlling and/or reducing the progression of myopia - Google Patents

Pharmaceutical compositions for controlling and/or reducing the progression of myopia

Info

Publication number
SG11202004005RA
SG11202004005RA SG11202004005RA SG11202004005RA SG11202004005RA SG 11202004005R A SG11202004005R A SG 11202004005RA SG 11202004005R A SG11202004005R A SG 11202004005RA SG 11202004005R A SG11202004005R A SG 11202004005RA SG 11202004005R A SG11202004005R A SG 11202004005RA
Authority
SG
Singapore
Prior art keywords
myopia
progression
reducing
controlling
pharmaceutical compositions
Prior art date
Application number
SG11202004005RA
Other languages
English (en)
Inventor
Monica Jong
Padmaja Rajagopal Sankaridurg
Minas Theodore Coroneo
Iii Earl Leo Smith
Amandeep Kaur
Original Assignee
Brien Holden Vision Institute Ltd
Minas Theodore Coroneo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brien Holden Vision Institute Ltd, Minas Theodore Coroneo filed Critical Brien Holden Vision Institute Ltd
Publication of SG11202004005RA publication Critical patent/SG11202004005RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts or implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202004005RA 2017-11-03 2018-11-02 Pharmaceutical compositions for controlling and/or reducing the progression of myopia SG11202004005RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581112P 2017-11-03 2017-11-03
PCT/AU2018/051187 WO2019084621A1 (en) 2017-11-03 2018-11-02 Pharmaceutical compositions for controlling and/or reducing the progression of myopia

Publications (1)

Publication Number Publication Date
SG11202004005RA true SG11202004005RA (en) 2020-05-28

Family

ID=66331107

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004005RA SG11202004005RA (en) 2017-11-03 2018-11-02 Pharmaceutical compositions for controlling and/or reducing the progression of myopia

Country Status (10)

Country Link
US (1) US20200345633A1 (https=)
EP (1) EP3703691A4 (https=)
JP (2) JP2021501803A (https=)
KR (1) KR20200088824A (https=)
CN (3) CN111787920A (https=)
AU (1) AU2018359013A1 (https=)
CA (1) CA3081593A1 (https=)
SG (1) SG11202004005RA (https=)
TW (1) TW201932104A (https=)
WO (1) WO2019084621A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3763280A1 (de) * 2019-07-11 2021-01-13 Carl Zeiss Vision International GmbH Bestimmung einer veränderung eines refraktionsfehlers eines auges
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
CN114306331B (zh) * 2020-10-10 2023-07-18 远大生命科学(武汉)有限公司 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途
US20240261291A1 (en) * 2021-06-11 2024-08-08 Brien Holden Vision Institute Limited Ophthalmic Compositions and/or Methods for Presbyopia, Mydriasis and/or Ocular Discomfort Management
WO2025259674A1 (en) * 2024-06-11 2025-12-18 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
CN119139472A (zh) * 2024-09-26 2024-12-17 温州医科大学附属眼视光医院 腺苷信号阻滞剂在制备治疗弱视和改善视觉可塑性的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG61430B1 (bg) * 1994-03-23 1997-08-29 Иван ХРИСТОВ антиастматично лекарствено средство
WO1995033451A1 (en) * 1994-06-06 1995-12-14 Warner-Lambert Company Non-sedating allergy sinus medication
US5574044A (en) * 1994-10-27 1996-11-12 Merck & Co., Inc. Muscarine antagonists
AU5312198A (en) * 1997-01-06 1998-08-03 Klaus Trier Aps Screening method
LT2493474T (lt) * 2009-10-30 2019-10-10 Intratus, Inc. Būdai ir kompozicijos prolonguotam vaistų įvedimui
WO2012161655A1 (en) * 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
JP5993620B2 (ja) * 2011-06-01 2016-09-14 ロート製薬株式会社 点眼剤
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition

Also Published As

Publication number Publication date
AU2018359013A1 (en) 2020-05-21
CN118384160A (zh) 2024-07-26
JP2023179418A (ja) 2023-12-19
WO2019084621A1 (en) 2019-05-09
CN111787920A (zh) 2020-10-16
US20200345633A1 (en) 2020-11-05
EP3703691A1 (en) 2020-09-09
JP2021501803A (ja) 2021-01-21
EP3703691A4 (en) 2021-07-28
KR20200088824A (ko) 2020-07-23
TW201932104A (zh) 2019-08-16
CA3081593A1 (en) 2019-05-09
CN118403054A (zh) 2024-07-30

Similar Documents

Publication Publication Date Title
HUE069999T2 (hu) Kompozíció miópia megelõzésében vagy szuppressziójában történõ alkalmazásra
SG11202004005RA (en) Pharmaceutical compositions for controlling and/or reducing the progression of myopia
IL271807A (en) New compounds and their pharmaceutical preparations for the treatment of leprosy
IL261444A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
SG11202103033WA (en) Compositions and methods for the treatment of presbyopia
IL272121A (en) Preparation and methods for the treatment of myopia
IL258032A (en) Compounds and preparations for the treatment of ocular disorders
EP3720421A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF METABOLIC DISEASES
EP3094284A4 (en) Compositions and methods for the treatment of intraocular neovascularization and/or leakage
EP3429584A4 (en) COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA
ZA202002066B (en) Compositions and methods for the treatment of eye disorders
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
EP3261446A4 (en) Methods and compositions for the treatment or prevention of parkinson's disease
IL269400A (en) Medicines and preparations for the treatment of eye disorders
EP3426671A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF INFECTIONS
SG11201809811VA (en) Compositions and methods for treatment of inflammation or infection of the eye
EP3716975A4 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
GB201702603D0 (en) Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3271320A4 (en) Compositions for the treatment of fibrosis and fibrosis-related conditions
IL265242B (en) Compounds for the treatment of hypertension and/or fibrosis
HK40031097A (en) Composition and methods for the treatment of myopia
AU2017901730A0 (en) Compositions for the Treatment of Diseases and Conditions
HK40034329A (en) Compositions and methods for the treatment of allergy
HK40033754A (en) Pharmaceutical compositions for the treatment of ophthalmic conditions
AU2016901682A0 (en) Compositions for the Treatment of Diseases and Conditions